Earnings Feed
Start Free
Home/Filings/4/0001062993-23-008326
4//SEC Filing

Leonard John E. 4

Accession 0001062993-23-008326

CIK 0001205922other
View on SEC.govCompany Profile

Filed

Apr 2, 8:00 PM ET

Accepted

Apr 3, 4:35 PM ET

Size

14.9 KB

Accession

0001062993-23-008326

Insider Transaction Report

Form 4
Period: 2023-03-31
VACCINEX, INC.VCNX
Leonard John E.
SVP, Development
Transactions
  • Award

    Stock Option (Right to Buy)

    2023-03-31+20,000→ 20,000 total
    Exercise: $0.40Exp: 2033-03-30→ Common Stock (20,000 underlying)
Holdings

  • Stock Option (Right to Buy)

    Exercise: $7.10Exp: 2025-12-23→ Common Stock (3,062 underlying)
    3,062

  • Common Stock

    2,258

  • Stock Option (Right to Buy)

    Exercise: $2.93Exp: 2031-04-02→ Common Stock (8,000 underlying)
    8,000

  • Stock Option (Right to Buy)

    Exercise: $3.90Exp: 2029-03-14→ Common Stock (3,000 underlying)
    3,000

  • Common Stock

    (indirect: By LLC)
    1,014

  • Stock Option (Right to Buy)

    Exercise: $7.10Exp: 2025-12-22→ Common Stock (23,150 underlying)
    23,150

  • Stock Option (Right to Buy)

    Exercise: $6.07Exp: 2030-02-24→ Common Stock (4,000 underlying)
    4,000

  • Stock Option (Right to Buy)

    Exercise: $1.29Exp: 2032-04-01→ Common Stock (16,000 underlying)
    16,000
Footnotes (5)
  • [F1]Exercisable in full as of the date of this report.
  • [F2]This option was granted under the Company's 2018 Omnibus Incentive Plan in a transaction exempt under Rule 16b-3 and, except as otherwise provided in the award notice, vests one-fourth on each of the first four anniversaries of the February 25, 2020 grant date.
  • [F3]This option was granted under the Company's 2018 Omnibus Incentive Plan in a transaction exempt under Rule 16b-3 and, except as otherwise provided in the award notice, vests one-fourth on each of the first four anniversaries of the April 2, 2021 grant date.
  • [F4]This option was granted under the Company's 2018 Omnibus Incentive Plan in a transaction exempt under Rule 16b-3 and, except as otherwise provided in the award notice, vests one-fourth on each of the first four anniversaries of the April 1, 2022 grant date.
  • [F5]This option was granted under the Company's 2018 Omnibus Incentive Plan in a transaction exempt under Rule 16b-3 and, except as otherwise provided in the award notice, vests one-fourth on each of the first four anniversaries of the March 31, 2023 grant date.

Documents

1 file

Issuer

VACCINEX, INC.

CIK 0001205922

→
Entity typeother

Related Parties

1
  • filerCIK 0001747997

Filing Metadata

Form type
4
Filed
Apr 2, 8:00 PM ET
Accepted
Apr 3, 4:35 PM ET
Size
14.9 KB
View on SEC.gov